In 2022, KDIGO’s diabetes in CKD guidelines recommended long-acting GLP-1 RAs for T2D patients with CKD who need additional glycemic or weight control despite metformin and an SGLT2 inhibitor [68]. Here, GLP1R is linked to diabetes mellitus.